Btg International Limited

British Technology Group Limited

Burroughs Wellcome Co.

Cambridge Enterprise Limited

Glaxo Wellcome Inc.

Glaxo Wellcome Inc. Research

Michael Ronald Clark

Herman Waldmann

Scott David Gorman

Gregory Paul Winter

Lutz Riechmann

Stephen Paul Cobbold

Edward G Routledge

Sarah L Bolt

Kathryn Lesley Armour

Lorna McLeod Williamson

Lorna Mcleod Williamson

An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.

Altered antibodies and their preparation

Disclosed are binding molecules which are recombinant polypeptides containing: (i) a binding domain capable of binding a target molecule, and (ii) an effector domain having an amino acid sequence substantially homologous to all or part of a constant domain of a human immunoglobulin heavy chain; characterized in that the binding molecule is capable of binding the target molecule without triggering significant complement dependent lysis, or cell mediated destruction of the target, and more preferably wherein the effector domain is capable of specifically binding FcRn and/or Fc&#x3b3;RIIb. These are generally based on chimeric domains which are derived from two or more human immunoglobulin heavy chain CH2 domains domains. In preferred embodiments the regions 233-236, and 327-331, are modified, as are further residues to render the molecule null allotypic. Also disclosed are nucleic acids, host cells, production processes and materials, and uses. Pharmaceutical preparations are also disclosed.

Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis

An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species. An antibody which is capable of binding to human CD4 antigen is also provided together with a pharmaceutical composition comprising the antibody.

Chimeric antibody, pharmaceutical composition and process of its production

Novel aglycosylated antibodies having a binding affinity for the CD3 antigen complex are of value for use in therapy, particularly in immunosuppression.

Humanized anti-CD3 specific antibodies

An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.

Antibodies to the antigen Campath-1

An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. 2, which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.

Growing community of inventors

Cambridge, United Kingdom

Michael Ronald Clark